c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations - Wikidata - wikimedia - TriplyDB

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

http://www.wikidata.org/entity/Q27649203

about

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Cancer driver mutations in protein kinase genes Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.Small molecule c-Met kinase inhibitors: a review of recent patents.Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma Fragment-based strategy for structural optimization in combination with 3D-QSAR.Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Disturbance of Ca2+ homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.Targeting the HGF/Met signaling pathway in cancer therapy Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening Targeting the Met signaling pathway in renal cancer.Targeted therapy for malignant glioma patients: lessons learned and the road ahead.HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.Kidney cancer pathology in the new context of targeted therapy.Progress and contrasts of the development of tivozanib for therapy of kidney cancer.Renal cell carcinoma deep sequencing: recent developments.Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.Molecular targets on the horizon for kidney and urothelial cancer.NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds.Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer Development of antibody-based c-Met inhibitors for targeted cancer therapy.

P2860

Q24608143-9FAA431E-409E-45E9-8D1B-7025DBF6A39F Q24610879-BCAEE92D-0204-47C1-97BD-6B2D67A038A7 Q27666642-66C8B7FA-83D5-46A8-BD2B-A5BF509A45F8 Q28821187-E74D60A2-27C8-4CFD-B992-5F03C468753D Q33556731-340D35A7-A4F9-4319-A667-EA6D6BAFD02C Q33645135-9AAF6EDE-4681-41C0-9372-BE75E9953003 Q33737789-D25E01C8-32A4-4DD0-AC2D-0AC7F9FEB1F4 Q33769437-6774FB26-6750-427B-85B6-8BD1EBF39890 Q33919087-9383DA05-5694-481D-99CF-1E843F8F3E8B Q34002709-48190A0E-37BD-458A-BD8A-4DE8B3300604 Q34080493-EC8295DA-E773-416A-871A-CA9938595A1E Q34094632-1CE4756A-09B6-4732-B496-E2D691E157DC Q34398276-7B8AA144-C5F3-4FE9-AE8C-57B5282C5C67 Q35030073-C06E3AC9-7386-4FB2-A34A-C8ADC48E2BF4 Q35221521-4796F8F4-B2FD-4A16-A58F-9BBF7658C3BC Q35525305-18FEE511-A2CD-45DB-8F61-E12E4BC8A95D Q35922491-2D94DCA5-048E-49E3-8DB4-01C397604D4A Q36228558-28369039-D74A-482A-9381-5CEABB79E37F Q36437161-217CEC50-C7AD-4F00-85DC-84CE735B4165 Q36766188-AD87BEA5-CDBC-4E1D-A79D-078794025518 Q37013777-30A47EB1-0728-4B89-82BB-7ACA7585D778 Q37078736-A3738FA2-62F2-48EF-8E8C-01B8601D6FBD Q37138521-1602BEE0-D7D5-4777-A624-7BD59F9A56D6 Q37183447-5A32BE1E-91EB-4432-83B6-26B4156B98B4 Q37231567-13B89787-1DA0-42D3-98E5-73B37845804D Q37331862-4A650844-4BB5-48FA-BE67-35021B1BD53F Q37533648-DA4A260A-691A-4082-8CEC-D41558A37EF4 Q37693742-20351577-B46C-4615-8EA7-4927007A8910 Q37730020-1B22980B-166A-41DC-B79F-08F3BE1D4032 Q37765586-953BC9EE-9596-4672-A356-236B3D5BD2CE Q37890209-1948BDEF-9484-45AB-A613-D788B1CFC47C Q37958038-C78CBF21-C13D-465D-A127-7D0B79CB135E Q38005625-7F158CE0-187E-4007-9C99-4AF1F826396F Q38022543-B67718D0-6B72-4FDD-9BCF-6727D4FF11B1 Q38132039-A993BBF9-D3D9-4DFD-81FA-147C7088D853 Q38445359-EA9673E5-A209-4E50-95EF-42317808828A Q38704262-FA1B2AAB-E408-43E5-92CB-43210DA697E1 Q38757070-E7ACD31A-3EE8-4C9B-A9A5-6EDD450A3B50 Q38858554-08CC6127-9E27-4FB5-B73D-730B1B3D3941 Q38912279-3E643D1A-B4FD-4881-8D74-8E16D191E067

P2860

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

http://www.wikidata.org/entity/Q27649203

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@ast

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@en

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@nl

type

label

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@ast

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@en

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@nl

prefLabel

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@ast

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@en

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@nl

P1433

Q27649203-1C208F7D-41AD-47E0-B676-4041B28E02AC

P1476

Q27649203-DDFEB265-3091-4394-8E48-042318287E5F

P2093

Q27649203-302AC78F-EE08-4953-9A59-143DC7DC63EF

Q27649203-40AC95BE-EF77-44AF-B0D1-C0EDE3E5C026

Q27649203-4D3480B2-A8F1-43F2-BF02-C5C18488E132

Q27649203-532E0C0E-EC73-458B-842E-2AA17542B54C

Q27649203-7EBA6AB5-2D50-4928-A217-DE17B8B5FEC5

Q27649203-8F449E26-475C-48E7-8C98-512AE1F9D5B3

Q27649203-8F82796F-1590-4274-8CF2-7CE049261BFC

Q27649203-90D6E930-0CBD-4D23-96CA-CDB333C4688A

Q27649203-A6F9E407-0503-45F5-BB85-E21E0F5609A9

Q27649203-AD6E2E6A-6F2A-41D1-BACB-D061B534A03D

P2860

Q27649203-069EBBBE-6411-48CE-82EF-8EEE72B38153

Q27649203-126F2640-D06C-4D4F-90AF-B65689E8703B

Q27649203-1878130E-A28F-4E3A-8752-DE06AF980DB9

Q27649203-1EC4997E-5DCB-4F23-93EC-87351FFCB080

Q27649203-20425B27-45C5-4F28-AFFC-7F9CFB2044AD

Q27649203-22262E38-0629-478D-BDA5-5BECA09855A8

Q27649203-25EE76D2-9785-47A6-B7FE-1A432F79D4BC

Q27649203-28D68C9D-1720-47A1-811C-6C3C0AED6828

Q27649203-2DB2734B-D98A-4329-B36D-9BEE7EDF6DA8

Q27649203-3765735C-2550-4D53-B253-4141F26436F8

P304

Q27649203-9B218816-687D-489F-82C7-D4C6C946B7FE

P31

Q27649203-D3ED7D1E-3FE4-475D-AF4E-34B9B1056D94

P3181

Q27649203-A637C331-3520-4954-9DD4-B6FAC6C9BC07

P356

Q27649203-193ED21C-7A58-489F-8378-CABAA0B26476

P407

Q27649203-D074CB0B-E42A-4A0A-97A3-297989839530

P433

Q27649203-EBF7EC98-8049-49B8-9FDB-11B324D7C340

P478

Q27649203-DA4AA633-CCD0-475C-AA26-4ED5461D67CE

P577

Q27649203-4DA080E3-376E-483D-9DDE-59AFAD3CD156

P5875

Q27649203-0D702415-BE69-41E7-BD08-5BB155BDBC81

P698

Q27649203-049E1150-DC77-46A0-BB5F-60DDF4095830

P3181

P356

P1433

Journal of Biological Chemistry

P1476

c-Met inhibitors with novel bi ...... ll carcinoma-related mutations

@en

P2093

Alexander M Long

http://www.w3.org/2001/XMLSchema#string

Andrew Tasker

http://www.w3.org/2001/XMLSchema#string

Angela Coxon

http://www.w3.org/2001/XMLSchema#string

Anne B O'Connor

http://www.w3.org/2001/XMLSchema#string

Carol W Johnson

http://www.w3.org/2001/XMLSchema#string

Isabelle Dussault

http://www.w3.org/2001/XMLSchema#string

Jodi Moriguchi

http://www.w3.org/2001/XMLSchema#string

Karen Rex

http://www.w3.org/2001/XMLSchema#string

Paul E Rose

http://www.w3.org/2001/XMLSchema#string

Paula Kaplan-Lefko

http://www.w3.org/2001/XMLSchema#string

P2860

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

Processing of X-ray diffraction data collected in oscillation mode

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

P304

2675-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4905132

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M705774200

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

283

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5793583

http://www.w3.org/2001/XMLSchema#string

P698

18055465

http://www.w3.org/2001/XMLSchema#string